►Click here to download the original poster (PDF)
L. TALON1, V. FOURNEYRON1, A. TRAPANI1, T. SINEGRE1 and A. LEBRETON1,2
1 Hématologie biologique, CHU Clermont Ferrand, Clermont Ferrand, France
2 Unité de nutrition humaine, UMR 1019, INRAE Université d’Auvergne
The routine D-Dimer quantification to exclude venous thromboembolism has led to the development of many assays, the usefulness of which depends on their reliability and performance.
To evaluate the analytical performances of the Yumizen G DDi 2 assay (HORIBA Medical) performed with the Yumizen G800 analyzer and to compare it with other available D-Dimer assays: Vidas D-Dimer Exclusion II for VIDAS® 3 (BioMérieux), STA®-Liatest® D-Di Plus for STA-R Max® (Diagnostica Stago), Innovance® D-Dimer for Sysmex® CS 2100 i (Siemens Healthineers) HemosIL® D-Dimer HS 500 for ACL TOP 700 (Werfen).
Within-run and between-run imprecision were evaluated using low- and high quality control plasma samples. The limit of detection, limit of quantification and linearity were determined according to the Clinical and Laboratory Standards Institute guidelines1. Interference due to hemolysis, icterus, lipemia, rheumatoid factor (RF) or heterophilic antibodies (HAMA) was evaluated by spiking plasma samples with hemolysate, bilirubin, Intralipid®, RF, or HAMA2. The measurements obtained with the different D-Dimer assays were compared with the Bland Altman plot method.
The coefficients of variation values of within- and between- run were in accordance with the specifications by Ricos and colleagues: <3% for D-Dimer values >1000 ng/mL fibrinogen-equivalent units (FEU) and <6% for D-Dimer values close to the threshold of 500 ng/mL FEU. The assay linearity was very good for a broad range of concentrations, up to 32700 ng/mL FEU. Hemolysis and icterus did not have any effect up to 10 g/L hemoglobin and 300 mg/L bilirubin. Lipemia seemed to generate an underestimation of D-Dimer concentration when Intralipid® concentration was >5 g/L (Figure 1). RF and HAMA did not have any effect. The Bland Altman analysis showed strong agreements between the Yumizen G DDi 2 assay and other assays performed with 66 fresh plasma samples with a wide range of D-Dimer concentrations. Discordant values were found in D-Dimer values >2000 ng/mL FEU, without clinical impact.
Figure 1: Bias (%) in D-Dimer measurement in function of hemoglobin (1A), bilirubin (1B) and lipid (1C) levels. Dotted lines represent the limit of acceptable bias. Each color corresponds to a plasma sample, and the different points correspond to the different concentrations of hemoglobin, bilirubin and intralipid spiked in the samples.
Figure 2: Bland Altman plots of the D-Dimer values obtained with the Yumizen G DDi 2 assay and the Yumizen G800 analyzer and other available assays. The X axis represents the mean of the measurements and the Y axis represents the difference between the measurements obtained with the two systems. Continuous and dotted lines represent the bias and the lower and upper limits of agreement with the 95% confidence intervals, respectively.
Its analytical performances and main technical features indicate that the new Yumizen G DDi 2 is suitable for the rapid quantification of D-Dimers in clinical laboratories.
1 Clinical and Laboratory Institute (CLSI). Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; approved guideline. 2nd Edition. CLSI Document EP17 A2 2012. https://clsi.org/standards/products/method-evaluation/documents/ep17/ (accessed December 9, 2020).
2 Nougier C, Jousselme E, Sobas F, Pousseur V, Négrier C. Effects of hemolysis, bilirubin, and lipemia interference on coagulation tests detected by two analytical systems. Int J Lab Hematol 2020;42:88 94.
Do you have any questions or requests? Use this form to contact our specialists.
